Search results
Showing 1 to 9 of 9 results for erenumab
Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.
In development [GID-TA10992] Expected publication date: 15 May 2024
Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.
Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.
Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.
TA076 Epilepsy (adults) - newer drugs 19 January 2004 TBC Erenumab for treating migraine 4 December 2019 TA854 Esketamine for...
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
145,000 people in England to have further treatment choice for preventing migraine attacks.
NICE has for the first time recommended an oral treatment for preventing migraines.
NICE has today (4 February 2020) published the outcome of the appeal against its final draft guidance (FAD) on erenumab (also called Aimovig and made by Novartis) for preventing chronic migraine.